Evaxion Extends Cash Runway to H2 2027, Posts 75% Response in Melanoma Vaccine
Evaxion extended its cash runway into the second half of 2027 through financings and partnerships and delivered 75% objective and 25% complete response rates in two-year Phase 2 data for the EVX-01 melanoma vaccine. CEO Helen Tayton-Martin says the AI-Immunology platform is now sharpened on oncology and infectious disease assets.
1. Financial Resilience and Runway Extension
Evaxion has secured funding through recent financings and strategic partnerships, extending its cash runway into the second half of 2027 and ensuring resources for ongoing clinical trials and platform development.
2. Positive Phase 2 EVX-01 Melanoma Vaccine Data
Two-year Phase 2 results for the EVX-01 cancer vaccine in advanced melanoma showed a 75% objective response rate and a 25% complete response rate, demonstrating robust clinical efficacy and strong immune activation profiles.
3. Strategic Focus and Pipeline Challenges
CEO Helen Tayton-Martin confirmed a sharpened focus on high-value oncology and infectious disease assets while exploring autoimmune disease applications; however, regulatory uncertainties around EVX-04 and limited internal capacity to advance multiple candidates independently pose challenges.
4. Partnerships and Platform Recognition
Evaxion strengthened its infectious disease portfolio through collaborations with MSD and the Gates Foundation, despite MSD not exercising its option on EVX-B2, and its AI-Immunology platform received recognition from the Galien Foundation for advances in human health.